Akari Therapeutics And Peak Bio Announce Portfolio Prioritization Plan For Combined Go-Forward Merger Entity
- Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease
- Akari Therapeutics announces leadership changes in separate Akari press release